In this review we address to what extent computational techniques can augment our ability to predict toxicity. The first section provides a brief history of empirical observations on toxicity dating back to the dawn of Sumerian civilization. Interestingly, the concept of dose emerged very early on, leading up to the modern emphasis on kinetic properties, which in turn encodes the insight that toxicity is not solely a property of a compound but instead depends on the interaction with the host organism. The next logical step is the current conception of evaluating drugs from a personalized medicine point-of-view. We review recent work on integrating what could be referred to as classical pharmacokinetic analysis with emerging systems biology approaches incorporating multiple omics data. These systems approaches employ advanced statistical analytical data processing complemented with machine learning techniques and use both pharmacokinetic and omics data. We find that such integrated approaches not only provide improved predictions of toxicity but also enable mechanistic interpretations of the molecular mechanisms underpinning toxicity and drug resistance. We conclude the chapter by discussing some of the main challenges, such as how to balance the inherent tension between the predicitive capacity of models, which in practice amounts to constraining the number of features in the models versus allowing for rich mechanistic interpretability, i.e. equipping models with numerous molecular features. This challenge also requires patient-specific predictions on toxicity, which in turn requires proper stratification of patients as regards how they respond, with or without adverse toxic effects. In summary, the transformation of the ancient concept of dose is currently successfully operationalized using rich integrative data encoded in patient-specific models.
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humans. Tox-21c largely overlaps with 3Rs (replace, reduce, and refine) proposed half a century ago [32, 33] . The Systems Toxicology computational challenge, sbv IMPROVER computational challenge, used crowd resourcing to demonstrate that gene expression data from blood cells are sufficiently informative to predict response to smoking in humans and across species translation [34] .
Yet, a comprehensive understanding of the mechanisms of drug toxicity in specific cases requires the integration of different data modalities, from changes at the genomic, proteomic, and metabolomics level across several scales of cellular organization. In contrast to classical approaches, systems toxicology resides at the intersection of systems biology and toxicology where chemistry incorporates mechanisms into the predictive framework [35] . To understand how this complex interaction system in cells and tissues leads to toxicity requires the integration of two disciplines that have been increasingly useful in biomedical research: "Systems Biology" and "Quantitative Pharmacology". In systems biology, a system is generally described as a set of nodes (vertices) connected by edges describing functional interactions. These edges can represent physical interactions, functional interactions, and connections between data across several scales. Similarly, in systems toxicology biological networks are the basis for the prediction of drug action in complex biological systems [36] .
Systems toxicology models contain expressions that characterize functional interactions within a biological network, which are very useful when drugs act at multiple targets in the network or when homeostatic feedback mechanisms are operative [37] . Therefore, these models are particularly useful in describing complex patterns of drug action such as synergies between different drugs. Although systems toxicology is still in its infancy, it has tremendous potential to change the way we approach biomedical research. It represents a movement beyond a traditional studycentric approach towards a continuous quantitative integration of data across studies and the different phases of drug development. Network-based approaches offer a wide range of possibilities for deciphering and possibly for understanding the complexity of human disease, thereby providing new tools with which to develop novel drugs. Here we review some current efforts and recent methods through the lens of quantitative systems pharmacology (QSP).
Examples of Predictive Systems Toxicology
The general notion of a network-based approach rests upon the ambition to connect several entities across the molecular, cellular pathways, organs and systems to facilitate the prediction of the effect of a drug candidate or any kind of perturbation on biological outcomes of interest [38, 39] . The way in which one defines or infers a network from data is the main determining factor of the degree of reliability and applicability of network analysis in drug design. It is crucial to have a clear definition of network nodes early on, edges and edge weights in the specific application case, and in that context to consider data quality and refinements of the data based on genetic variability, aging, environmental effects. Different types of networks such as networks of chemical compounds, signaling networks, gene-gene interaction networks, proteinprotein interaction (PPI) networks or metabolic networks and disease networks can be (and have been) used in QSP models and methods [40] . Following the work on inferring a network comes the analysis of the network and its properties. In the last step, the result of analysis needs to be converted to a series of actionable hypotheses, which then need to be tested and validated or refuted (see Fig1).
Drug-target interaction is the first and most common type of network analysis that has been used in QSP models. Interactions between drugs and targets can facilitate the process of drug discovery by deciphering a drug's mechanism of action, thereby assisting researchers seeking new targets for an old (FDA approved) drug as well as new drug candidates for a known target [41] [42] [43] [44] [45] . The main source of information in reconstruction of the Drug-Target interaction network (DTN) is the Drug Bank, which is one of the major publicly available integrated sources of drugs and targets. It is a highly comprehensive database combining chemical properties and detailed clinical information about drugs and their targets. It also provides drug-related data feeds for well-known databases such as Uniprot, PubChem, PDB and KEGG [46, 47] .
In spite of the fact that mining drug-target interaction data is increasing at an amazing off-targets by docking the drug into protein binding pockets similar to those of its primary target, followed by mapping the proteins with the best docking scores to known biological pathways, thus predicting potential side effects [53] .Classically, the process starts with a target of known three-dimensional structure, and docking is used to predict the bound conformation and binding energy. In most cases, the three-dimensional structure of a target is needed to compute the binding of each drug candidate to the target, which for many targets are still unavailable [54] [55] [56] . Wallach et al. have developed a method to mitigate the impact of this important limitation. They utilize a dataset where there is a pairing of drugs with their observed adverse drug reactions (ADRs), the protein structure database and in silico virtual docking to identify putative protein targets for each drug and search for correlated pairs of side effects and biological pathways [57] . Another challenge when performing docking simulation is that it is computationally expensive and most of the methods must simplify the problem to drug and target as a vector of latent variables and assigns weights to drug-target interactions using probabilistic matrix factorization [64] . Approaches that use similarity scores as input are more promising than other approaches [41] .
In general, the use of machine-learning algorithms is one of most promising approaches to extracting knowledge from big data using a data-driven framework.
However, the performance of machine-learning algorithms relies heavily on data representations called features, and identifying which features are more appropriate for the given task is very difficult. Deep Learning has recently emerged as a promising technique where the features do not need to be hand-crafted a priori. Recent success has been accomplished thanks to the availability of fast computations, massive (labeled) datasets and sophisticated algorithms [65] . Machine learning using deep learning is defined by neural networks with multiple hidden layers. Each layer basically constructs a feature from the preceding layers [66] . The training process allows layers deeper in the network to contribute to the refinement of earlier layers. For this reason, these algorithms can automatically engineer or discover features that are suitable for representing the data at hand. When sufficient data are available, these methods construct features attuned to a specific problem and combine those features into a predictor [67] . Deep learning algorithms have shown promise in fields as diverse as high-energy physics [68] , dermatology [69] , and translation [70] . DEEPtox is one of the first methods using Deep Learning for computational toxicity prediction [65] . DeepTox normalizes the chemical representations of the compounds and computes a large number of chemical descriptors that are used as input in machine learning methods.
As a next step, DeepTox trains several models, evaluates them, and combines the best of them into ensembles. Finally, DeepTox predicts the toxicity of new compounds.
In DEEPTox SVMs, random forests, and elastic nets are used for cross-checking, [72] have followed the same approach to studying the drug-target interaction and could characterize the drug-target relations of different kinds of drugs. They showed that the number of multi-target new molecular entities (NME) has increased over the years, but less than single-target NMEs. In both these cases and several other cases in the literature, it has proven useful to analyze the general structure of a network in order to extract new knowledge facilitating the classification of drugs and/or their targets. Structural (graphical) analysis of a network provides insights into the organization and topology of the DTN and targets for hypothesis generation and experimental testing. As a rule this is performed through computation and analysis of network parameters-parameters that quantify different aspects of the network's internal structure, such as parameters measuring centrality, a node or more global parameters such as modularity index, network density, network entropy or network diameter [73] . Several methods have been developed and applied based on network topology, graph theory, and cluster analysis (see [8] for a recent review). Methods based on the similarity of networks is another set of techniques that have been used to uncover novel target or disease-specific changes [74, 75] . A wide range of similarity measures have been used in the literature, ranging from intuitive measures such as the number of edge changes required to get one network from another or the comparison of the top-k nodes to the more complicated ones, such as using an ensemble of different model networks, and the distribution of the best-fitting ensemble.
However, it should be kept in mind that the fundamental question of checking whether two given networks have the same structure, network comparison, is computationally expensive, and despite extensive progress in the field, it remains one of the greatest challenges in the field. For example, it is still not known whether graph isomorphism is polynomial solvable or whether it is NP-complete. Therefore most of the current methods in the network comparison field are heuristic, which in turn may affect the outcome strongly, depending on which kind of prior biases exist in the particular method. Similarly, several other approaches have been developed based on the notion of expanded drug-target interactions, combined with protein-protein interactions data, in order to develop a network-based pharmacology that could better explain the drugphenotype relationship, and this approach has been used to predict novel targets and drug repositioning [80] [81] [82] [83] [84] [85] . For example, Guney et al. in [86] integrated protein-protein interaction, drug-disease association and drug-target association data. They analyzed the topological characteristics of drug targets with respect to disease proteins and showed that for a drug to be effective against a disease, it had to target proteins within or in the immediate vicinity of the corresponding disease module. Such approaches were also considered for issues related to drug safety and side effects. Cami et al.
constructed a network representation of drug-ADR associations for approximately 800 drugs and ADRs and pharmacological information for toxicity prediction. They exploited network structure to predict likely unknown adverse events using a trained logistic regression model [87] . Berger et al. used PPI networks to predict and identify drugs that likely cause Long QT Syndrome based on both a direct drug-target interaction and separate neighborhood [88] .
Complementary to protein-protein interactions, transcriptomic data and gene expression differentiation have been used in drug discovery and safety [88] [89] [90] [91] [92] [93] . between drug targets to predict the pharmacodynamics of drug-drug interactions [92, 93] .
For the purpose of predicting drug toxicity, in most cases we require a collection of experimental data reflecting molecular changes in the context of quantifiable cellular changes across different biological scales that are linked to toxicity at the body level [35] . So in addition to all the above-mentioned data, systems toxicology depends strongly on the quality and scope of databases annotating side effects (SIDER) and drug-induced differential gene expression, or a combination thereof [94] [95] [96] [97] . Using this score, we could rank all possible combinations in a reasonable amount of time. Interestingly, we learned that we should not include too many details (i.e. features or molecular components) in our network descriptions, since we may shift our description from optimal towards the 'knowledge of everything,' with the precision of the method dropping drastically as a result. This underscores the importance and challenge of pruning a large, but for the given application reasonable number of features to include in the network model. Signal transduction_Additional pathways of NF-kB activation (in the cytoplasm) 1,391E-09
Fig. 2 Overview of HotPPI approach

Information theoretic approach to toxicity
Both network analysis and pharmacokinetic analysis share a focus and grounding in the physical and functional interactions between molecules within the cell or tissue and the corresponding drugs. Here the overarching aim is not only to predict but also to be able to interpret the mechanism in terms of the underlying biology and chemistry. Since the design of new drugs for new targets is difficult, and the prediction problem is easier from an inference point-of-view, compared to elucidating the mechanisms driving toxicity, complementary approaches are warranted. For example, instead of engineering a drug to target the unique pathways or mutations of a tiny subset of diseases, drug repositioning, such as the one exemplified in the DREAM challenge, involves starting with approved drugs to find combinations that can be used to treat diseases different from the ones they have been designed for, with the advantage that approved drugs can bypass much regulation if correctly controlling for the effects they can have. Thus prediction and simulation are key. This means that the whole field has to move towards causal modeling and functional inference rather than traditional statistical classification (e.g. Tanimoto coefficients) or computational simulation based on classical geometric approaches (e.g. distance between molecules, grid-based docking). To this end, information indexes can facilitate the characterization of drugs by the combinatorial and structural properties shared with or at a remove from the structural properties of the targets, because just as for any molecule, structure means function. Then all these approaches can contribute to determining drug function based on the fact that structurally similar molecules usually have similar properties (known as "neighborhood behavior"). For example, statins are associated with the heart and cholesterol, while morphine, codeine and heroin share structural properties and effects. However, algorithmic information-theoretic approaches based on both classical information and computability theory introduce predictive causal models that go beyond statistical similarities and can find, in principle, similar mechanisms shared by sets of drugs with respect to targets and functions.
It is not difficult to see that complementary regions between drug and target will have a similar classical and algorithmic information content, because the structure of one is the complement of the other. Another advantage is that these measures are parameter-free and thus require no training, even though they can complement and guide machine learning approaches [101, 102] . Because drug docking is not invariant to, e.g., scaling factors, but information theoretic measures are, they may fail to characterize the positive or negative docking properties of a drug. While coarsegraining techniques may be introduced, algorithmic complexity has the advantage of being able to account for scaling effects. The basic idea is the likelihood of a drug being causally generated by a mechanistic model (an algorithm). This is, in general, hard if not impossible to find (the problem is uncomputable), but approximations are possible and new numerical methods have been advanced complementary to statistical and lossless compression approaches that cannot or are very limited at accounting for causation. Drugs, and molecules in general, can be represented in many ways (see the less complex (the shorter the length of the algorithm generating it) the closer to blue, the longer (more algorithmic-random) the closer to red.
Concluding remarks
Here we have reviewed different attempts to predict toxicity from observations (i.e. the Sumerian) to classical pharmacokinetic, advancing to recent integrative systems oriented approaches taking more data into account. These systems approaches resort to performing advanced statistical analytical data processing complemented with machine learning techniques to generate paradigms attempting not only to predict toxicity but also to identify (molecular) mechanisms of toxicity. Information theoretic approaches can be situated in between, as they are as a rule less dependent upon biochemical representations in their problem formulation, while the ones presented here also aim for causal understanding of toxicity in addition to targeting prediction.
In a broader perspective, there are several immediate challenges where we need more work. These include which features to include when predicting toxicity? Minimal models may suffer from being less understandable from a mechanistic standpoint, whereas including too many features, as in the dream example above, could hamper the prediction capability of the model. Overall, a systems biology approach extends the feature space compared to classical pharmacokinetics, while an (algorithmic) information approach facilitates predictions in combination, being both scale invariant and parameter free. Hence there is a tension between predicitive capacity and mechanistic interpretability.
Furthermore, overtraining and overfitting in solving high-dimensional and complex nonlinear problems such as toxicity prediction is one of the most common problems of existing machine learning methods. This originates from the need for estimating and optimizing numerous hyper parameters. However, a method such as the relevance vector machine method solves this problem by incorporating Bayesian criteria into the learning process to reduce the irrelevant support vectors of the decision boundary in feature space, thus resulting in a sparser model [103] . Methods such as Random Forest classifiers are another category of successful methods in systems toxicology. They are one of the most robust algorithms and are able to identify the patterns important for the preferred class, even when there is a large imbalance in the class distribution within the training dataset [104] . Inspecting the results of the TOX21 data challenge demonstrates that a hybrid strategy which combines similarity scores for structural fingerprints and molecular descriptors (features) and machine-learning based prediction models can readily improve the accuracies of toxicity prediction [105] . In general, an ensemble model can be effective, since taking into account the prediction of other models can compensate for an incorrect prediction on the part of one of the individual methods. Certainly, each of the systems toxicology methods has intrinsic advantages, limitations, and practical constraints. Moreover, the performance of these methods depends on the structural diversity and representativeness of the molecules in the data set. Therefore, it is quite important to choose the most suitable machine learning method to develop the prediction model for a specific toxicity data set. Finally, the computational cost associated with each method is another practical and important factor determining the usability of a given method.
In conclusion, beyond the above challenges and considerations, the grand remaining challenge is to advance the state-of-the-art towards personalized medicine. This requires patient specific predictions on toxicity, which in turn requires proper stratification of patients with regard to how they respond or not, with or without adverse toxic effects. This most likely requires integration of multiple layers of information as a background upon which an individual has to be characterized/described, while a machinery for toxicity prediction has to be specific enough for a given patient, given the amount of (sparse) patient-specific information. This challenge and perspective will keep the field of data-driven computational toxicology busy. 
